However, when the glycosylation is removed from PD-1, the tumor’s sensitivity to the drug is restored (58), and the combined use of GB1211 (a Gal-3 inhibitor) with PD-L1 inhibitors can effectively eliminate Gal-3-induced resistance to pembrolizumab and atezolizumab, thereby enhancing their therapeutic effectiveness (59). This evidence concerns the gene LGALS3 and neoplasm.